nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—NF2—meningioma	0.0706	0.0706	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—TSHB—meningioma	0.0277	0.0277	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CST3—meningioma	0.0199	0.0199	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—SMO—meningioma	0.0179	0.0179	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—ERBB2—meningioma	0.0166	0.0166	CbGpPWpGaD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—ERBB2—meningioma	0.0129	0.0129	CbGpPWpGaD
Temsirolimus—FKBP1A—TOR Signaling—AKT1—meningioma	0.0126	0.0126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—PGR—meningioma	0.0116	0.0116	CbGpPWpGaD
Temsirolimus—MTOR—CD28 dependent PI3K/Akt signaling—AKT1—meningioma	0.0109	0.0109	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—PDGFB—meningioma	0.0107	0.0107	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—ERBB2—meningioma	0.0104	0.0104	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—PDGFB—meningioma	0.00962	0.00962	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—PDGFB—meningioma	0.00939	0.00939	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—PDGFB—meningioma	0.00932	0.00932	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—PDGFB—meningioma	0.0091	0.0091	CbGpPWpGaD
Temsirolimus—MTOR—FSH signaling pathway—AKT1—meningioma	0.00889	0.00889	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—PLAU—meningioma	0.00883	0.00883	CbGpPWpGaD
Temsirolimus—MTOR—VEGFR2 mediated vascular permeability—AKT1—meningioma	0.00863	0.00863	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—meningioma	0.00817	0.00817	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—ERBB2—meningioma	0.00799	0.00799	CbGpPWpGaD
Temsirolimus—MTOR—CD28 co-stimulation—AKT1—meningioma	0.00776	0.00776	CbGpPWpGaD
Temsirolimus—MTOR—Alpha 6 Beta 4 signaling pathway—AKT1—meningioma	0.00757	0.00757	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AP1B1—meningioma	0.00747	0.00747	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AP1B1—meningioma	0.00744	0.00744	CbGpPWpGaD
Temsirolimus—MTOR—LKB1 signaling events—TP53—meningioma	0.00725	0.00725	CbGpPWpGaD
Temsirolimus—MTOR—Class I PI3K signaling events mediated by Akt—AKT1—meningioma	0.00722	0.00722	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—PDGFB—meningioma	0.00719	0.00719	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—ERBB2—meningioma	0.00716	0.00716	CbGpPWpGaD
Temsirolimus—MTOR—TOR Signaling—AKT1—meningioma	0.00706	0.00706	CbGpPWpGaD
Temsirolimus—MTOR—IL2 signaling events mediated by PI3K—AKT1—meningioma	0.00691	0.00691	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—PDGFB—meningioma	0.00688	0.00688	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—PDGFB—meningioma	0.00677	0.00677	CbGpPWpGaD
Temsirolimus—MTOR—CXCR3-mediated signaling events—AKT1—meningioma	0.00676	0.00676	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00672	0.00672	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—PDGFB—meningioma	0.00647	0.00647	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—ERBB2—meningioma	0.00645	0.00645	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—PDGFB—meningioma	0.00644	0.00644	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—PDGFB—meningioma	0.0064	0.0064	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—PDGFB—meningioma	0.00637	0.00637	CbGpPWpGaD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—AKT1—meningioma	0.00636	0.00636	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—ERBB2—meningioma	0.0063	0.0063	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PDGFB—meningioma	0.00628	0.00628	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—ERBB2—meningioma	0.00625	0.00625	CbGpPWpGaD
Temsirolimus—MTOR—IFN-gamma pathway—AKT1—meningioma	0.00613	0.00613	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—PTEN—meningioma	0.0061	0.0061	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB2—meningioma	0.0061	0.0061	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—meningioma	0.00605	0.00605	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—PDGFB—meningioma	0.006	0.006	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PDGFB—meningioma	0.006	0.006	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—PDGFB—meningioma	0.006	0.006	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—PDGFB—meningioma	0.00594	0.00594	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—PDGFB—meningioma	0.00589	0.00589	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—PDGFB—meningioma	0.00586	0.00586	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—meningioma	0.00575	0.00575	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.00573	0.00573	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—AKT1—meningioma	0.00571	0.00571	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—PDGFB—meningioma	0.00555	0.00555	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—PTEN—meningioma	0.0055	0.0055	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—PTEN—meningioma	0.00537	0.00537	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—PTEN—meningioma	0.00533	0.00533	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PDGFB—meningioma	0.00531	0.00531	CbGpPWpGaD
Temsirolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—meningioma	0.00526	0.00526	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—meningioma	0.00521	0.00521	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—PTEN—meningioma	0.0052	0.0052	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—PTEN—meningioma	0.0052	0.0052	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD34—meningioma	0.00505	0.00505	CbGpPWpGaD
Temsirolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—meningioma	0.00503	0.00503	CbGpPWpGaD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—AKT1—meningioma	0.00503	0.00503	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CTSL—meningioma	0.00502	0.00502	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—TP53—meningioma	0.00497	0.00497	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—meningioma	0.00483	0.00483	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—ERBB2—meningioma	0.00482	0.00482	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CTSL—meningioma	0.00482	0.00482	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—meningioma	0.00461	0.00461	CbGpPWpGaD
Temsirolimus—MTOR—IL4-mediated signaling events—AKT1—meningioma	0.00457	0.00457	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—ERBB2—meningioma	0.00454	0.00454	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AP1B1—meningioma	0.00453	0.00453	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CST3—meningioma	0.00443	0.00443	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—meningioma	0.0044	0.0044	CbGpPWpGaD
Temsirolimus—MTOR—mTOR signaling pathway—AKT1—meningioma	0.00435	0.00435	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—AKT1—meningioma	0.00435	0.00435	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—ERBB2—meningioma	0.00434	0.00434	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—meningioma	0.00433	0.00433	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—meningioma	0.00431	0.00431	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—ERBB2—meningioma	0.00431	0.00431	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—ERBB2—meningioma	0.00429	0.00429	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—ERBB2—meningioma	0.00427	0.00427	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—AKT1—meningioma	0.00425	0.00425	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—AKT1—meningioma	0.00425	0.00425	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00421	0.00421	CbGpPWpGaD
Temsirolimus—MTOR—SREBP signalling—AKT1—meningioma	0.0042	0.0042	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—AKT1—meningioma	0.0042	0.0042	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AP1B1—meningioma	0.00419	0.00419	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—PTEN—meningioma	0.00411	0.00411	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PDGFB—meningioma	0.00408	0.00408	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00402	0.00402	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—ERBB2—meningioma	0.00402	0.00402	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—ERBB2—meningioma	0.00402	0.00402	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—ERBB2—meningioma	0.00398	0.00398	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—meningioma	0.00395	0.00395	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—PTEN—meningioma	0.00393	0.00393	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—ERBB2—meningioma	0.00393	0.00393	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—AKT1—meningioma	0.00393	0.00393	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00391	0.00391	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—meningioma	0.00389	0.00389	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—PTEN—meningioma	0.00387	0.00387	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—meningioma	0.00373	0.00373	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—ERBB2—meningioma	0.00372	0.00372	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—PTEN—meningioma	0.00372	0.00372	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—PTEN—meningioma	0.0037	0.0037	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—meningioma	0.00368	0.00368	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—PTEN—meningioma	0.00368	0.00368	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—PTEN—meningioma	0.00366	0.00366	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—PTEN—meningioma	0.00364	0.00364	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00359	0.00359	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—AKT1—meningioma	0.00359	0.00359	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00359	0.00359	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00356	0.00356	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—meningioma	0.00355	0.00355	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00352	0.00352	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—PTEN—meningioma	0.00343	0.00343	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—PTEN—meningioma	0.00343	0.00343	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00343	0.00343	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—PTEN—meningioma	0.0034	0.0034	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—PTEN—meningioma	0.00337	0.00337	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—PTEN—meningioma	0.00335	0.00335	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.0033	0.0033	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TSHB—meningioma	0.00327	0.00327	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—PTEN—meningioma	0.00317	0.00317	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—AKT1—meningioma	0.00317	0.00317	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—AKT1—meningioma	0.00309	0.00309	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—AKT1—meningioma	0.00307	0.00307	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD34—meningioma	0.00306	0.00306	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00304	0.00304	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—AKT1—meningioma	0.003	0.003	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.003	0.003	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—meningioma	0.00295	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTSL—meningioma	0.00292	0.00292	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—AKT1—meningioma	0.00279	0.00279	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMO—meningioma	0.00278	0.00278	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—ERBB2—meningioma	0.00274	0.00274	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALAD—meningioma	0.0027	0.0027	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PGR—meningioma	0.00267	0.00267	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—meningioma	0.00266	0.00266	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HES1—meningioma	0.0026	0.0026	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CST3—meningioma	0.00249	0.00249	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—AKT1—meningioma	0.00237	0.00237	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PTEN—meningioma	0.00233	0.00233	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PDGFB—meningioma	0.00233	0.00233	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—AKT1—meningioma	0.00233	0.00233	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—meningioma	0.00227	0.00227	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—meningioma	0.00224	0.00224	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PDGFB—meningioma	0.00224	0.00224	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—AKT1—meningioma	0.00223	0.00223	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PDGFB—meningioma	0.00223	0.00223	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—AKT1—meningioma	0.00214	0.00214	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—AKT1—meningioma	0.00213	0.00213	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—AKT1—meningioma	0.00212	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.00212	0.00212	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—AKT1—meningioma	0.00211	0.00211	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—AKT1—meningioma	0.0021	0.0021	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.00207	0.00207	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—AKT1—meningioma	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—AKT1—meningioma	0.00197	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—AKT1—meningioma	0.00196	0.00196	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALAD—meningioma	0.00195	0.00195	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—meningioma	0.00194	0.00194	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—AKT1—meningioma	0.00193	0.00193	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—meningioma	0.00187	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TSHB—meningioma	0.00184	0.00184	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—AKT1—meningioma	0.00183	0.00183	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HES1—meningioma	0.00182	0.00182	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.00175	0.00175	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TSHB—meningioma	0.00174	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—meningioma	0.0017	0.0017	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00163	0.00163	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMO—meningioma	0.00156	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—meningioma	0.00156	0.00156	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PDGFB—meningioma	0.00156	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PGR—meningioma	0.0015	0.0015	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—meningioma	0.0015	0.0015	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—meningioma	0.00149	0.00149	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALAD—meningioma	0.00147	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HES1—meningioma	0.00146	0.00146	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALAD—meningioma	0.00139	0.00139	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PDGFB—meningioma	0.00136	0.00136	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKT1—meningioma	0.00135	0.00135	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—meningioma	0.00133	0.00133	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—meningioma	0.00128	0.00128	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—meningioma	0.00127	0.00127	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TSHB—meningioma	0.00126	0.00126	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PDGFB—meningioma	0.00125	0.00125	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—meningioma	0.00105	0.00105	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HES1—meningioma	0.00103	0.00103	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TSHB—meningioma	0.000948	0.000948	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000947	0.000947	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—meningioma	0.000909	0.000909	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALAD—meningioma	0.000906	0.000906	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TSHB—meningioma	0.000893	0.000893	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—meningioma	0.000892	0.000892	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PDGFB—meningioma	0.000877	0.000877	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—meningioma	0.00084	0.00084	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.0008	0.0008	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—meningioma	0.000776	0.000776	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—meningioma	0.000767	0.000767	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—meningioma	0.000737	0.000737	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—meningioma	0.000734	0.000734	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—meningioma	0.000716	0.000716	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—meningioma	0.000608	0.000608	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—meningioma	0.000588	0.000588	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TSHB—meningioma	0.000584	0.000584	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—meningioma	0.000514	0.000514	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—meningioma	0.000501	0.000501	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—meningioma	0.000473	0.000473	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—meningioma	0.000447	0.000447	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—meningioma	0.000413	0.000413	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—meningioma	0.000342	0.000342	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—meningioma	0.000342	0.000342	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—meningioma	0.000289	0.000289	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—meningioma	0.000273	0.000273	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—meningioma	0.000258	0.000258	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—meningioma	0.000243	0.000243	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—meningioma	0.000197	0.000197	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—meningioma	0.000159	0.000159	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—meningioma	0.000149	0.000149	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—meningioma	0.00014	0.00014	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—meningioma	9.17e-05	9.17e-05	CbGpPWpGaD
